

# Samit R Joshi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3033335/publications.pdf>

Version: 2024-02-01

8  
papers

110  
citations

1478505

6  
h-index

1588992

8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

32  
citing authors

| # | ARTICLE  | IF  | CITATIONS |
|---|--|-----|-----------|
| 1 | Lack of pharmacokinetic interaction between the HIV-1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1704-1712.                     | 2.4 | 5         |
| 2 | Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254. <i>Clinical Infectious Diseases</i> , 2022, 75, 786-794.           | 5.8 | 12        |
| 3 | Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants. <i>Clinical Pharmacology in Drug Development</i> , 2022, 11, 632-639.  | 1.6 | 5         |
| 4 | Phase I evaluation of pharmacokinetics and tolerability of the HIV-1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3501-3507.                        | 2.4 | 12        |
| 5 | A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, . | 3.2 | 11        |
| 6 | Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next-generation HIV-1 maturation inhibitor. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00671.                                     | 2.4 | 21        |
| 7 | Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study. <i>PLoS ONE</i> , 2019, 14, e0224076.  | 2.5 | 15        |
| 8 | Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 primary analysis from a randomized Phase IIb trial. <i>PLoS ONE</i> , 2018, 13, e0205368.          | 2.5 | 29        |